Geron Is Dead in the Water, but Not Sunk Yet

Onetime stem cell stalwart Geron Corp. (NASDAQ: GERN  ) , which has since reinvented itself as an oncology company, may have just lost its only oncology drug. The stock plunged 60% today after the FDA placed a total clinical hold on imetelstat in both of its phase 2 trials for separate blood cancer indications, because of a low-grade but persistent increase in liver enzymes across all patients in the trial. The FDA needs to know about the reversability and seriousness of these liver toxicity issues before allowing the drug to proceed.

In this video, Motley Fool health-care analyst David Williamson discusses why Geron is dead in the water as long as the FDA hold persists. While there is a possibility that investors could see a nice pop if the FDA does give the all-clear at some point in the future, investing on that thesis is about as risky as it gets. If the FDA nixes imetelstat completely, David says he doesn't see anything here that would keep Geron afloat.

Pharmaceutical stocks can crater, hard. Why not look to this great 2014 pick instead?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 12, 2014, at 7:49 PM, kdipal wrote:

    I am surprised that anyone would make strong statements about GERN, when author does not have any knowledge about the data both from company and or from FDA. Question about the validity and its judgment that may misguide investors.

  • Report this Comment On March 13, 2014, at 8:16 AM, ellaerdos wrote:

    "don't have the full data"

    "in my opinion"

    These statements tell the investor nothing, All they they do is cause a market overreaction.

    Long on GERN

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2873901, ~/Articles/ArticleHandler.aspx, 11/25/2014 11:19:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement